Partner, Life Sciences
SarsiaCheck size: NOK 2M-NOK 5M in a first round and up to NOK 30M-NOK 40M over time, as published by Sarsia.
Farzad Abdi-Dezfuli invests or supports investment decisions through Sarsia's published strategy: Build early Norwegian science and technology companies in life science, energy and sustainability through specialist capital and active ownership.
Defensible science or technology, capable teams, large markets and a credible path from early validation to international scale.
Opportunities outside life science, technology, energy and sustainability, or without a defensible knowledge advantage, are less aligned.
Show the science or technology, validation, intellectual property, market, team and the milestones funded by the first NOK 2M-NOK 5M.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Farzad Abdi-Dezfuli is a current Partner, Life Sciences at Sarsia, according to the firm's official roster. No additional biography is inferred where the firm does not publish one.